belzutifan (Welireg) plus pembrolizumab (Keytruda): FDA status

Approved Approved Jun 12, 2025. Indication: adjuvant clear cell renal cell carcinoma after nephrectomy. Company: Merck.

Regulatory history

All products in the FDA Tracker

Loading today's edition…